AZILECT's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7815942 | TEVA | Rasagiline formulations of improved content uniformity |
Aug, 2027
(3 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7572834 | TEVA | Rasagiline formulations and processes for their preparation |
Dec, 2026
(3 years from now) | |
Azilect is owned by Teva.
Azilect contains Rasagiline Mesylate.
Azilect has a total of 2 drug patents out of which 0 drug patents have expired.
Azilect was authorised for market use on 16 May, 2006.
Azilect is available in tablet;oral dosage forms.
Azilect can be used as treatment of parkinson's disease.
The generics of Azilect are possible to be released after 27 August, 2027.
Drugs and Companies using RASAGILINE MESYLATE ingredient
Market Authorisation Date: 16 May, 2006
Treatment: Treatment of parkinson's disease
Dosage: TABLET;ORAL
More Information on Dosage
AZILECT family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic